454 related articles for article (PubMed ID: 18707718)
1. Can we accurately identify men with low risk prostate cancer?
Neal DE
J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
[No Abstract] [Full Text] [Related]
2. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Thompson IM; Ankerst DP; Etzioni R; Wang T
J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
[No Abstract] [Full Text] [Related]
3. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
D'Amico AV; Chen MH
J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
[No Abstract] [Full Text] [Related]
5. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
[TBL] [Abstract][Full Text] [Related]
6. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen dynamics and prostate cancer diagnosis.
Bartoletti R
Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
[No Abstract] [Full Text] [Related]
8. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
[TBL] [Abstract][Full Text] [Related]
9. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels < or = 10 ng/ml.
Stephan C; Jung K; Cammann H
Cancer; 2004 May; 100(9):1989-90; author reply 1989-90. PubMed ID: 15112283
[No Abstract] [Full Text] [Related]
10. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
Johnson L
Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
[No Abstract] [Full Text] [Related]
11. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
[TBL] [Abstract][Full Text] [Related]
12. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
13. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
14. Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy?
Van Poppel H
Eur Urol; 2009 May; 55(5):1012-3. PubMed ID: 19261377
[No Abstract] [Full Text] [Related]
15. Estimated impact of the prostate cancer prevention trial on population mortality.
Zeliadt SB; Etzioni R; Kristal AR
Cancer; 2005 Oct; 104(7):1556-7; author reply 1557. PubMed ID: 16015625
[No Abstract] [Full Text] [Related]
16. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
Höltl W; Lunglmayr G
Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
[No Abstract] [Full Text] [Related]
17. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
Stephan C; Schnorr D; Loening SA; Jung K
Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
[No Abstract] [Full Text] [Related]
18. Editorial comment.
Eyre SJ
J Urol; 2011 Feb; 185(2):488. PubMed ID: 21167520
[No Abstract] [Full Text] [Related]
19. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer: 4. Screening.
Meyer F; Fradet Y
CMAJ; 1998 Oct; 159(8):968-72. PubMed ID: 9834724
[No Abstract] [Full Text] [Related]
[Next] [New Search]
